Posters

    Sytems toxicological-based assessment of sex-related differences in response to cigarette smoke within an OECD rat inhalation study

    Kogel, U.; Sewer, A.; Vuillaume, G.; Boue, S.; Talikka, M.; Wong, E. T.; Hayes, W. S.; Vanscheeuwijck, P.; Hoeng, J.; Peitsch, M. C.

    Conference date
    Mar 22, 2015
    Conference name

    Society of Toxicology (SOT) 2015
    Topic
    Summary

    Cigarette smoking is a major risk factor for the development of respiratory diseases. Several observations suggest that different genders may have a different susceptibility for lung diseases. Sex differences in regards to exposure susceptibility and sensitivity may be present because of morphological differences between female and male lungs and/or may be due to the effects of differences in levels of sex hormones. For example adult female rats have more and smaller alveoli than males thereby providing them with larger alveolar surface area to body mass ratios, whereas adult male mice have larger absolute lung volumes than females but smaller volume to body mass ratios which likely influence the response to inhaled toxicants. In order to gain insights into the sex-related differences in response to cigarette mainstream smoke (CS), a 90-day rat inhalation study, as described in the Organization for Economic Co-operation and Development (OECD) guideline 413, was augmented with multi-analyte profiling of the bronchoalveolar lavage fluid (BALF) and transcriptomics analysis of lung tissue. The comparison between female and male rats in regard to some respiratory-related endpoints are shown here.

    Related Publications

    Physiologically based Pharmacokinetic Modeling of Nicotine from Inhaled Aqueous Aerosol Predicts Marked Gastrointestinal Absorption in Rats

    Systems Toxicology Pre-clinical Toxicology

    Structural, functional, and molecular impact on the cardiovascular system in ApoE-/- mice exposed to aerosol from candidate modified risk tobacco products, Carbon Heated Tobacco Product 1.2 and Tobacco Heating System 2.2, compared with cigarette smoke

    Systems Toxicology Pre-clinical Toxicology

    In vitro high-content imaging-based phenotypic analysis of bronchial 3D organotypic air–liquid interface cultures

    Systems Toxicology Pre-clinical Toxicology

    Impact of sample preparation upon intracellular metabolite measurements in 3D cell culture systems

    Systems Toxicology Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.